following an efficacy assessment, the investigator may administer a booster dose every 8 weeks based on efficacy and tolerability. Treliplimab was administered at a dose of 240 mg per infusion via int
Sponsors
West China Hospital, Sichuan University
Conditions
Melanoma
Phase 1
Safety and Efficacy of YMN-V117 Formulation in patients with advanced melanoma who previously failed immunotherapy: A Phase I, Single-Arm, Open-Label, Prospective Clinical Study
Active, not recruitingChiCTR2600123328
Start: 2026-06-01Updated: 2026-05-04
Safety and Efficacy of YMN-V115 Formulation in patients with advanced melanoma who previously failed immunotherapy: A Phase I, Single-Arm, Open-Label, Prospective Clinical Study
Active, not recruitingChiCTR2600123828
Start: 2026-05-06Updated: 2026-05-04